Satellos Gets FDA Fast Track Status For Duchenne Drug
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL ) (" Satellos " or the " Company "), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatmen